TY - JOUR
T1 - High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment
AU - Berger Fridman, Ilana
AU - Kostas, James
AU - Gregus, Michal
AU - Ray, Somak
AU - Sullivan, Matthew R.
AU - Ivanov, Alexander R.
AU - Cohen, Smadar
AU - Konry, Tania
N1 - Funding Information:
The authors are grateful for the support provided by the National Institutes of Health grants under awards numbers 1R33CA223908-01 and 1R01GM127714-01A1 (awarded to T.K.), R01GM120272 , R01CA218500 , and R35GM136421 (awarded to A.R.I.), and by the National Science Foundation under Grant No. G00005964 (awarded to T. K.). The authors would like to thank Northeastern University for providing seed funding support through the Tier 1 program (A.R.I. and T.K.). I.B.F gratefully acknowledges the Negev fellowship from Kreitman School. This work was done in partial fulfillment of the requirements for a Ph.D. degree (I.B.F) at the Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Israel. Prof. Cohen holds the Claire and Harold Oshry Professor Chair in Biotechnology. We thank the Institute for Chemical Imaging of Living Systems at Northeastern University and the confocal imaging core facility at Beth Israel Deaconess medical center for consultation and imaging support.
Funding Information:
The authors are grateful for the support provided by the National Institutes of Health grants under awards numbers 1R33CA223908-01 and 1R01GM127714-01A1 (awarded to T.K.), R01GM120272, R01CA218500, and R35GM136421 (awarded to A.R.I.), and by the National Science Foundation under Grant No. G00005964 (awarded to T. K.). The authors would like to thank Northeastern University for providing seed funding support through the Tier 1 program (A.R.I. and T.K.). I.B.F gratefully acknowledges the Negev fellowship from Kreitman School. This work was done in partial fulfillment of the requirements for a Ph.D. degree (I.B.F) at the Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Israel. Prof. Cohen holds the Claire and Harold Oshry Professor Chair in Biotechnology. We thank the Institute for Chemical Imaging of Living Systems at Northeastern University and the confocal imaging core facility at Beth Israel Deaconess medical center for consultation and imaging support.
Publisher Copyright:
© 2021
PY - 2021/9/15
Y1 - 2021/9/15
N2 - Cancer is driven by both genetic aberrations in the tumor cells and fundamental changes in the tumor microenvironment (TME). These changes offer potential targets for novel therapeutics, yet lack of in vitro 3D models recapitulating this complex microenvironment impedes such progress. Here, we generated several tumor-stroma scaffolds reflecting the dynamic in vivo breast TME, using a high throughput microfluidic system. Alginate (Alg) or alginate-alginate sulfate (Alg/Alg-S) hydrogels were used as ECM-mimics, enabling the encapsulation and culture of tumor cells, fibroblasts and immune cells (macrophages and T cells, of the innate and adaptive immune systems, respectively). Specifically, Alg/Alg-S was shown capable of capturing and presenting growth factors and cytokines with binding affinity that is comparable to heparin. Viability and cytotoxicity were shown to strongly correlate with the dynamics of cellular milieu, as well as hydrogel type. Using on-chip immunofluorescence, production of reactive oxygen species and apoptosis were imaged and quantitatively analyzed. We then show how macrophages in our microfluidic system were shifted from a proinflammatory to an immunosuppressive phenotype when encapsulated in Alg/Alg-S, reflecting in vivo TME dynamics. LC-MS proteomic profiling of tumor cells sorted from the TME scaffolds revealed upregulation of proteins involved in cell-cell interactions and immunomodulation in Alg/Alg-S scaffolds, correlating with in vivo findings and demonstrating the appropriateness of Alg/Alg-S as an ECM biomimetic. Finally, we show the formation of large tumor-derived vesicles, formed exclusively in Alg/Alg-S scaffolds. Altogether, our system offers a robust platform for quantitative description of the breast TME that successfully recapitulates in vivo patterns. Statement of significance: Cancer progression is driven by profound changes in both tumor cells and surrounding stroma. Here, we present a high throughput microfluidic system for the generation and analysis of dynamic tumor-stroma scaffolds, that mimic the complex in vivo TME cell proportions and compositions, constructing robust in vitro models for the study of the TME. Utilizing Alg/Alg-S as a bioinspired ECM, mimicking heparin's in vivo capabilities of capturing and presenting signaling molecules, we show how Alg/Alg-S induces complex in vivo-like responses in our models. Alg/Alg-S is shown here to promote dynamic protein expression patterns, that can serve as potential therapeutic targets for breast cancer treatment. Formation of large tumor-derived vesicles, observed exclusively in the Alg/Alg-S scaffolds suggests a mechanism for tumor survival.
AB - Cancer is driven by both genetic aberrations in the tumor cells and fundamental changes in the tumor microenvironment (TME). These changes offer potential targets for novel therapeutics, yet lack of in vitro 3D models recapitulating this complex microenvironment impedes such progress. Here, we generated several tumor-stroma scaffolds reflecting the dynamic in vivo breast TME, using a high throughput microfluidic system. Alginate (Alg) or alginate-alginate sulfate (Alg/Alg-S) hydrogels were used as ECM-mimics, enabling the encapsulation and culture of tumor cells, fibroblasts and immune cells (macrophages and T cells, of the innate and adaptive immune systems, respectively). Specifically, Alg/Alg-S was shown capable of capturing and presenting growth factors and cytokines with binding affinity that is comparable to heparin. Viability and cytotoxicity were shown to strongly correlate with the dynamics of cellular milieu, as well as hydrogel type. Using on-chip immunofluorescence, production of reactive oxygen species and apoptosis were imaged and quantitatively analyzed. We then show how macrophages in our microfluidic system were shifted from a proinflammatory to an immunosuppressive phenotype when encapsulated in Alg/Alg-S, reflecting in vivo TME dynamics. LC-MS proteomic profiling of tumor cells sorted from the TME scaffolds revealed upregulation of proteins involved in cell-cell interactions and immunomodulation in Alg/Alg-S scaffolds, correlating with in vivo findings and demonstrating the appropriateness of Alg/Alg-S as an ECM biomimetic. Finally, we show the formation of large tumor-derived vesicles, formed exclusively in Alg/Alg-S scaffolds. Altogether, our system offers a robust platform for quantitative description of the breast TME that successfully recapitulates in vivo patterns. Statement of significance: Cancer progression is driven by profound changes in both tumor cells and surrounding stroma. Here, we present a high throughput microfluidic system for the generation and analysis of dynamic tumor-stroma scaffolds, that mimic the complex in vivo TME cell proportions and compositions, constructing robust in vitro models for the study of the TME. Utilizing Alg/Alg-S as a bioinspired ECM, mimicking heparin's in vivo capabilities of capturing and presenting signaling molecules, we show how Alg/Alg-S induces complex in vivo-like responses in our models. Alg/Alg-S is shown here to promote dynamic protein expression patterns, that can serve as potential therapeutic targets for breast cancer treatment. Formation of large tumor-derived vesicles, observed exclusively in the Alg/Alg-S scaffolds suggests a mechanism for tumor survival.
KW - 3D disease models
KW - Biomaterials
KW - Breast cancer
KW - Proteomic profiling
KW - Tumor microenvironment
KW - microfluidics
UR - http://www.scopus.com/inward/record.url?scp=85109102743&partnerID=8YFLogxK
U2 - 10.1016/j.actbio.2021.06.025
DO - 10.1016/j.actbio.2021.06.025
M3 - Article
C2 - 34153511
AN - SCOPUS:85109102743
SN - 1742-7061
VL - 132
SP - 473
EP - 488
JO - Acta Biomaterialia
JF - Acta Biomaterialia
ER -